[HTML][HTML] Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
MJE Marshall, RJ Stopforth… - Frontiers in …, 2017 - pubmed.ncbi.nlm.nih.gov
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
[HTML][HTML] Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
MJE Marshall, RJ Stopforth, MS Cragg - Frontiers in Immunology, 2017 - ncbi.nlm.nih.gov
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
[引用][C] Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
MJE Marshall, RJ Stopforth, MS Cragg - Frontiers in Immunology, 2017 - cir.nii.ac.jp
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We
Going? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Going? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF][PDF] Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?
MJE Marshall, R Stopforth, MS Cragg - Frontiers in Immunology, 2017 - eprints.soton.ac.uk
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
MJE Marshall, RJ Stopforth, MS Cragg - Frontiers in Immunology, 2017 - europepmc.org
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
MJE Marshall, RJ Stopforth, MS Cragg - Frontiers in Immunology, 2017 - europepmc.org
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …